Status:
UNKNOWN
Relationship Between Plasma Metabolome and the Efficacy of Systemic Glucocorticoid in AECOPD
Lead Sponsor:
Peking University Third Hospital
Conditions:
COPD
COPD Exacerbation Acute
Eligibility:
All Genders
18+ years
Brief Summary
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) significantly increases the mortality of the patients with COPD. Guidelines have recommended systemic glucocorticoid as regular tre...
Detailed Description
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) significantly increases the mortality of the patients with COPD. Guidelines have recommended systemic glucocorticoid as regular tre...
Eligibility Criteria
Inclusion
- Patients who meet the diagnostic criteria for acute exacerbation of chronic obstructive pulmonary disease in GOLD 2016 and require hospitalization.
Exclusion
- Bronchial asthma, bronchiectasis and other airflow obstructive diseases;
- Combined with community-acquired pneumonia, hospital-acquired pneumonia or aspiration pneumonia;
- Combined with severe liver and kidney insufficiency;
- Malignant tumor;
- Immune deficiency due to chemotherapy or HIV infection;
- Received systemic hormone therapy due to acute exacerbation of chronic obstructive pulmonary disease within 1 month before this admission;
- Severe trauma or stress, etc.
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04710849
Start Date
February 1 2021
End Date
June 1 2024
Last Update
January 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, China, 100191